From the Journals

SPRINT’s intensive therapy benefit fades once BP creeps back up


 

FROM JAMA CARDIOLOGY

Factors driving rising BP are unclear

There is limited information on what medications were taken by either group following the end of the trial, so the reason for the regression in the intensive treatment arm after leaving the trial is unknown. The authors speculated that this might have been due to therapeutic inertia among treating physicians, poor adherence among patients, the difficulty of keeping blood pressures low in patients with advancing pathology, or some combination of these.

“Perhaps the most important reason was that providers and patients were not aiming for the lower goals since guidelines did not recommend these targets until 2017,” Dr. Cushman pointed out. He noted that Healthcare Effectiveness Data and Information Set (HEDIS) “has still not adopted a performance measure goal of less than 140 mm Hg.”

In an accompanying editorial, the authors focused on what these data mean for population-based strategies to achieve sustained control of one of the most important risk factors for cardiovascular events. Led by Daniel W. Jones, MD, director of clinical and population science, University of Mississippi, Jackson, the authors of the editorial wrote that these data emphasized “the challenge of achieving sustained intensive BP reductions in the real-world setting.”

Dr. Daniel W. Jones, director of clinical and population science, University of Mississippi, Jackson

Dr. Daniel W. Jones

Basically, the editorial concluded that current approaches to achieving meaningful and sustained blood pressure control are not working.

This study “should be a wakeup call, but other previously published good data have also been ignored,” said Dr. Jones in an interview. Despite the compelling benefit from intensive blood pressure control the SPRINT trial, the observational follow-up emphasizes the difficulty of maintaining the rigorous reductions in blood pressure needed for sustained protection.

“Systemic change is necessary,” said Dr. Jones, reprising the major thrust of the editorial he wrote with Donald Clark III, MD, and Michael E. Hall, MD, who are both colleagues at the University of Mississippi.

“My view is that health care providers should be held responsible for motivating better compliance of their patients, just as a teacher is accountable for the outcomes of their students,” he said.

The solutions are not likely to be simple. Dr. Jones called for multiple strategies, such as employing telehealth and community health workers to monitor and reinforce blood pressure control, but he said that these and other data have convinced him that “simply trying harder at what we currently do” is not enough.

Dr. Pajewski and Dr. Jones report no potential conflicts of interest. Dr. Cushman reports a financial relationship with ReCor.

Pages

Recommended Reading

Heart failure drug a new treatment option for alcoholism? 
MDedge Cardiology
How to improve diagnosis of HFpEF, common in diabetes
MDedge Cardiology
Food insecurity a growing problem for many with CVD
MDedge Cardiology
Newer drugs not cost effective for first-line diabetes therapy
MDedge Cardiology
Salt pills for patients with acute decompensated heart failure?
MDedge Cardiology
Long-term antidepressant use tied to an increase in CVD, mortality risk
MDedge Cardiology
Nifedipine during labor controls BP in severe preeclampsia
MDedge Cardiology
Bariatric surgery prompts visceral fat reduction, cardiac changes
MDedge Cardiology
Dapagliflozin DELIVERs regardless of systolic pressure in HFpEF
MDedge Cardiology
Trial of early intensive meds at HF discharge halted for benefit: STRONG-HF
MDedge Cardiology